Additional file 3: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S1. Comparison of somatic mutation frequency between IBC and non-IBC in four subgroups. (a) The percentage of samples with somatic mutation in the TNBC subgroup; (b) the percentage of samples with somatic mutation in the HR–/HER2+ subgroup; (c) the percentage of samples with somatic mutation in the HR+/HER2– subgroup; (d) the percentage of samples with somatic mutation in the HR+/HER2+ subgroup. The gray bars indicate non-IBC, the black bars indicate IBC; *p < 0.05, **p < 0.01, ***p < 0.001. (PDF 52 kb

Additional file 4: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S2. Comparison of biological pathway between IBC and non-IBC in four subgroups. (a) The percentage of samples with alteration on 10 biological pathways in the TNBC subgroup; (b) the percentage of samples with alteration on 10 biological pathways in the HR–/HER2+ subgroup; (c) the percentage of samples with alteration on 10 biological pathways in the HR+/HER2– subgroup; (d) the percentage of samples with alteration on 10 biological pathways in the HR+/HER2+ subgroup. The gray bars indicate non-IBC, the black bars indicate IBC; *p < 0.05, **p < 0.01, ***p < 0.001. (PDF 41 kb

DFX/VD association induces myeloid differentiation and increases overall survival in elderly AML patients.

<p>(A) Kaplan-Meier estimated OS in DFX/VD and BSC treated patients (B) Multivariate analysis. Forest plot of the odds ratio. (C) OS within subgroups presenting normal VD levels (≥50 nmol/L) or VD deficiency (≤50 nmol/L). (D) Monocytes numbers in VD/DFX treated patients (F) Creatinine levels in treated patients.</p

Table <b>1.</b> Baseline characteristics of patients.

<p>Table <b>1.</b> Baseline characteristics of patients.</p

Patient and tumor characteristics.

<p>Patient and tumor characteristics.</p

Adjuvant treatment recommendation pre- and post-Prosigna test results, by Prosigna test risk category.

<p>Adjuvant treatment recommendation pre- and post-Prosigna test results, by Prosigna test risk category.</p

Intrinsic tumor subtype results by physician judgement and Prosigna test results.

<p>Intrinsic tumor subtype results by physician judgement and Prosigna test results.</p